- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.07. | Century Therapeutics files $200M mixed shelf offering | 4 | Seeking Alpha | ||
| 07.07. | Century Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.06. | Century Therapeutics hält jährliche Aktionärsversammlung ab | 15 | Investing.com Deutsch | ||
| 16.06. | Century Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 28.05. | Century Therapeutics, Inc.: Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress | 13 | GlobeNewswire (USA) | ||
| 16.05. | Century Therapeutics GAAP EPS of $0.89, revenue of $109.16M | 2 | Seeking Alpha | ||
| CENTURY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.05. | Century Therapeutics, Inc.: Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | 219 | GlobeNewswire (Europe) | Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and... ► Artikel lesen | |
| 28.04. | Century Therapeutics, Inc.: Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting | 3 | GlobeNewswire (USA) | ||
| 24.04. | H.C. Wainwright maintains Buy rating on Century Therapeutics stock | 8 | Investing.com | ||
| 15.04. | Century Therapeutics, Inc.: Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025 | 12 | GlobeNewswire (USA) | ||
| 03.04. | H.C. Wainwright cuts Century Therapeutics target to $2 | 4 | Investing.com | ||
| 21.03. | Demystifying Century Therapeutics: Insights From 4 Analyst Reviews | 1 | Benzinga.com | ||
| 21.03. | Guggenheim cuts Century Therapeutics target to $5, keeps Buy rating | 2 | Investing.com | ||
| 20.03. | Century Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 19.03. | Century Therapeutics GAAP EPS of -$1.61 misses by $0.23, revenue of $6.59M beats by $3.24M | 2 | Seeking Alpha | ||
| 19.03. | Century Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.03. | Century Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 19.03. | Century Therapeutics, Inc.: Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update | 172 | GlobeNewswire (Europe) | Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell mediated autoimmune diseases and malignancies New concentrated... ► Artikel lesen | |
| 28.02. | Century Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.01. | Century Therapeutics, Inc.: Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned ... | 167 | GlobeNewswire (Europe) | - Investigator-initiated trial (IIT) to be led by pioneers of cell therapy in B-cell mediated autoimmune disease, the Schett/Mackensen group at Friedrich-Alexander University Erlangen-Nürnberg - -... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,778 | +1,35 % | Aktien Frankfurt Ausblick: Leichte Entspannung nach US-Arbeitsmarktschock | FRANKFURT (dpa-AFX) - Nach einem von Konjunktursorgen getriebenen Rückschlag dürfte sich der deutsche Aktienmarkt am Montag zunächst leicht erholen. Der X-Dax signalisierte für den hiesigen Leitindex... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,250 | 0,00 % | Palatin Technologies, Inc.: Palatin Announces 1-for-50 Reverse Stock Split | PRINCETON, N.J., Aug. 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT), today announced a reverse stock split ("Reverse Stock Split") of its... ► Artikel lesen | |
| BIOXXMED | 0,250 | 0,00 % | EQS-News: bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024 | EQS-News: bioXXmed AG
/ Schlagwort(e): Jahresbericht
bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024
27.06.2025 /... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| OCUGEN | 0,860 | +0,42 % | Ocugen sichert sich 20 Millionen US-Dollar über registrierte Direktplatzierung | ||
| VIKING THERAPEUTICS | 32,740 | +0,63 % | Doppelschlag mit Viking Therapeutics und Rheinmetall | An der Börse gibt es Momente, in denen wenige Tage über den Erfolg einer ganzen Strategie entscheiden. Wer solche Chancen erkennt und entschlossen handelt, kann in kurzer Zeit außergewöhnliche Ergebnisse... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| BIO-GATE | 0,880 | -6,38 % | Bio-Gate mit Verlust, Aktie stürzt ab | Bio-Gate hat die endgültigen Zahlen für 2024 vorgelegt. An der Börse kommen die Zahlen der Bilanz schlecht an: Die Bio-Gate Aktie notiert aktuell bei 0,82 Euro mit 20,39 Prozent im Minus. Das Unternehmen... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,361 | -2,96 % | Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer | Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
| ABIVAX | 60,30 | -0,33 % | Abivax, CRISPR Therapeutics und Revolution Medicines: Biotech im Höhenflug - das wikifolio ... | ||
| VAXART | 0,307 | 0,00 % | Vaxart, Inc.: Vaxart CEO Issues Letter to Stockholders | - Management Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on September 4, 2025 - SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart,... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,640 | -8,89 % | Burcon NutraScience Corporation: Burcon Achieves First Commercial Production of Fava Protein and Officially Launches FavaPro 90%+ Pure Plant Protein | Vancouver, British Columbia--(Newsfile Corp. - August 5, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 4,730 | +0,42 % | Cellectar Biosciences, Inc.: Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement | Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative... ► Artikel lesen | |
| GALAPAGOS NV | 27,860 | -0,07 % | Galapagos NV: Galapagos Creates New Subscription Right Plan | Mechelen, Belgium; August 7, 2025, 22.01
CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,800,000 subscription rights under... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 2,080 | +1,46 % | A Glimpse Into The Expert Outlook On Cardiff Oncology Through 4 Analysts |
CENTURY THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,026 (-4,88 %) liegt der Kurs bei 0,503 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CENTURY THERAPEUTICS INC finden Sie auf Wallstreet Online.